BlackRock Investment Management’s Aevi Genomic Medicine Inc GNMX Stock Holding History

BlackRock Investment Management’s Portfolio GNMX Stock Details GNMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$500K	Sell	96,621 -1,854	-2%	-$9.76K	﹤0.01%	3050
2016 Q3	$549K	Buy	98,475 +9,102	+10%	+$51.9K	﹤0.01%	3002
2016 Q2	$496K	Buy	89,373 +20,843	+30%	+$109K	﹤0.01%	3073
2016 Q1	$302K	Buy	68,530 +279	+0.4%	+$1.15K	﹤0.01%	3074
2015 Q4	$411K	Buy	68,251 +9,459	+16%	+$64.2K	﹤0.01%	3059
2015 Q3	$460K	Buy	58,792 +2,260	+4%	+$17.5K	﹤0.01%	3067
2015 Q2	$347K	Buy	56,532 +53,695	+1,893%	+$416K	﹤0.01%	3209
2015 Q1	$23K	Buy	2,837 +126	+5%	+$950	﹤0.01%	3410
2014 Q4	$14K	Buy	2,711 +447	+20%	+$2.21K	﹤0.01%	3565
2014 Q3	$12K	Buy	2,264 +145	+7%	+$936	﹤0.01%	3600
2014 Q2	$16K	Buy	+2,119	New	+$15K	﹤0.01%	3482

Other funds holding GNMX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

BlackRock Investment Management's GNMX Position: Q4 2016 in Review

BlackRock Investment Management reduced its Aevi Genomic Medicine Inc (GNMX) stake by 1.9% in Q4 2016, selling an estimated $9.76K and leaving 96,621 shares worth $500K. The position accounts for ﹤0.01% of the portfolio, ranked #3050.

BlackRock Investment Management first reported a position in GNMX in Q2 2014 and has held it in 11 quarters since. The position peaked at $549K in Q3 2016. 76 funds tracked by Wall St. Rank hold GNMX as of Q4 2016.

BlackRock Investment Management held 96,621 shares of Aevi Genomic Medicine Inc worth $500K as of Q4 2016.
BlackRock Investment Management sold 1,854 Aevi Genomic Medicine Inc shares in Q4 2016, an estimated $9.76K.
Aevi Genomic Medicine Inc made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3050 holding.
BlackRock Investment Management first reported a position in Aevi Genomic Medicine Inc in Q2 2014 and has held it in 11 quarters since.
BlackRock Investment Management's Aevi Genomic Medicine Inc position peaked at $549K in Q3 2016.
76 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.